MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β

다국어 초록 (Multilingual Abstract)

PD-L1 is abnormally regulated in many cancers and is critical for immune escape. Fully understanding the regulation of PD-L1 expression is vital for improving the clinical efficacy of relevant anticancer agents. TGF-β plays an important role in the low reactivity of PD-1/PD-L1 antibody immunotherapy. However, it is not very clear whether and how TGF-β affects PD-L1 expression. In the present study, we show that TGF-β upregulates the expression of the transcriptional coactivator MRTF-A in non-small-cell lung cancer cells, which subsequently interacts with NF-κB/p65 rather than SRF to facilitate the binding of NF-κB/p65 to the PDL1 promoter, thereby activating the transcription and expression of PD-L1. This leads to the immune escape of NSCLC cells. This process is dependent on the activation of the TGF-β signaling pathway. In vivo, inhibition of MRTF-A effectively suppresses the growth of lung tumor s y ngrafts with enrichment of NK and T cells in tumor tissue. Our study defines a new signaling pathway that regulates the transcription and expression of PD-L1 upon TGF-β treatment, which may have a significant impact on research into the application of immunotherapy in treating lung cancer.

참고문헌 (Reference)

1 Zhang, W. L., "miR-206 inhibits metastasisrelevant traits by degrading MRTF-A in anaplastic thyroid cancer" 47 : 133-142, 2015

2 Wu, Y., "eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA" 477 : 4367-4381, 2020

3 Dong, P., "Tumor-intrinsic PDL1 signaling in cancer initiation, development and treatment : beyond immune evasion" 8 : 386-, 2018

4 Morita, T., "Tumor progression is mediated by thymosin-beta4through a TGFbeta/MRTF signaling axis" 16 : 880-893, 2018

5 Löffek, S., "Transforming of the tumor microenvironment : implications for TGFbeta inhibition in the context of immune-checkpoint therapy" 2018 : 9732939-, 2018

6 Kang, J. H., "Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles" 34 : 2213-2226, 2020

7 He, H., "Transcription of HOTAIR is regulated by RhoC-MRTF-A-SRF signaling pathway in human breast cancer cells" 31 : 87-95, 2017

8 Pipes, G. C., "The myocardin family of transcriptional coactivators : versatile regulators of cell growth, migration, and myogenesis" 20 : 1545-1556, 2006

9 He, H., "The Wnt-beta-catenin signaling regulated MRTF-A transcription to activate migration-related genes in human breast cancer cells" 9 : 15239-15251, 2018

10 Lu, C., "The MLL1-H3K4me3 axis-mediated pd-l1 expression and pancreatic cancer immune evasion" 109 : 6-, 2017

11 Constantinidou, A., "Targeting programmed cell death-1(PD-1)and ligand(PD-L1) : a new era in cancer active immunotherapy" 194 : 84-106, 2019

12 Mariathasan, S., "TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells" 554 : 544-548, 2018

13 Caraci, F., "TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts" 57 : 274-282, 2008

14 Miranda, M. Z., "TGF-beta1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism" 292 : 14902-14920, 2017

15 Fabregat, I., "TGF-beta signaling in cancer treatment" 20 : 2934-2947, 2014

16 Derynck, R., "Smad-dependent and Smad-independent pathways in TGF-beta family signalling" 425 : 577-584, 2003

17 Chen, L. F., "Shaping the nuclear action of NF-kappaB" 5 : 392-401, 2004

18 Brahmer, J. R., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer" 366 : 2455-2465, 2012

19 Sabbatino, F., "Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma : a case report and review of the literature" 6 : 126-, 2018

20 Shi, Y., "Regulatory mechanisms of PD-L1 expression in cancer cells" 67 : 1481-1489, 2018

21 Chen, J., "Regulation of PD-L1 : a novel role of prosurvival signalling in cancer" 27 : 409-416, 2016

22 Li, F., "Preliminary mechanisms of regulating PDL1 expression in nonsmall cell lung cancer during the EMT process" 40 : 775-782, 2018

23 Herbst, R. S., "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients" 515 : 563-567, 2014

24 Wang, D. Z., "Potentiation of serum response factor activity by a family of myocardin-related transcription factors" 99 : 14855-14860, 2002

25 Viatour, P., "Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation" 30 : 43-52, 2005

26 Garon, E. B., "Pembrolizumab for the treatment of non-small-cell lung cancer" 372 : 2018-2028, 2015

27 Zou, W., "PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations" 8 : 328-324, 2016

28 Tumeh, P. C., "PD-1 blockade induces responses by inhibiting adaptive immune resistance" 515 : 568-571, 2014

29 Keir, M. E., "PD-1 and its ligands in tolerance and immunity" 26 : 677-704, 2008

30 Alsaab, H. O., "PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy : mechanism, combinations, and clinical outcome" 8 : 561-, 2017

31 Bi, J., "NK cell dysfunction and checkpoint immunotherapy" 10 : 1999-, 2019

32 Mistriotis, P., "NANOG reverses the myogenic differentiation potential of senescent stem cells by restoring ACTIN filamentous organization and SRFdependent gene expression" 35 : 207-221, 2017

33 Medjkane, S., "Myocardinrelated transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis" 11 : 257-268, 2009

34 Crider, B. J., "Myocardin-related transcription factors A and B are key regulators of TGF-beta1-induced fibroblast to myofibroblast differentiation" 131 : 2378-2385, 2011

35 Parmacek, M. S., "Myocardin-related transcription factors : critical coactivators regulating cardiovascular development and adaptation" 100 : 633-644, 2007

36 Yu, O. M., "Myocardin-related transcription factor A and yes-associated protein exert dual control in G protein-coupled receptor-and RhoA-mediated transcriptional regulation and cell proliferation" 36 : 39-49, 2016

37 Tang, R. H., "Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression" 105 : 3362-3367, 2008

38 Posern, G., "Mutant actins that stabilise F-actin use distinct mechanisms to activate the SRF coactivator MAL" 23 : 3973-3983, 2004

39 Mittermeier, C., "Molecular mechanisms to target cellular senescence in hepatocellular carcinoma" 9 : 12-, 2020

40 Kleffel, S., "Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth" 162 : 1242-1256, 2015

41 Meng, C., "MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells" 104 : 718-728, 2018

42 Iwai, Y., "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade" 99 : 12293-12297, 2002

43 Li, C. W., "Glycosylation and stabilization of programmed death ligand-1suppresses T-cell activity" 7 : 12632-, 2016

44 Hugo, W., "Genomic and transcriptomic features of response to anti-PD-1therapy in metastatic melanoma" 165 : 35-44, 2016

45 Jung, A. R., "Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma" 10 : 3652-, 2020

46 Morita, T., "Dual roles of myocardin-related transcription factors in epithelial mesenchymal transition via slug induction and actin remodeling" 179 : 1027-1042, 2007

47 Abbas, A. B., "Design and synthesis of A PD-1 binding peptide and evaluation of its anti-tumor activity" 20 : 3-, 2019

48 Liu, Q., "DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis" 11 : 53-, 2018

49 Hsu, J., "Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1blockade" 128 : 4654-4668, 2018

50 Rodriguez-Ubreva, J., "Chromatin immunoprecipitation" 1094 : 309-318, 2014

51 O’Connor, J. W., "Cell-cell contact and matrix adhesion promote alphaSMA expression during TGFbeta1-induced epithelial-myofibroblast transition via Notch and MRTF-A" 6 : 26226-, 2016

52 Burr, M. L., "CMTM6 maintains the expression of PD-L1 and regulates antitumour immunity" 549 : 101-105, 2017

53 Zhang, J., "Biochemical aspects of PD-L1 regulation in cancer immunotherapy" 43 : 1014-1032, 2018

54 Pawlowski, R., "An actin-regulated importin alpha/beta-dependent extended bipartite NLS directs nuclear import of MRTF-A" 29 : 3448-3458, 2010

55 Ribas, A., "Adaptive immune resistance : how cancer protects from immune attack" 5 : 915-919, 2015

56 Smyth, M. J., "Activation of NK cell cytotoxicity" 42 : 501-510, 2005

57 Miralles, F., "Actin dynamics control SRF activity by regulation of its coactivator MAL" 113 : 329-342, 2003